N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nykode Therapeutics ASA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Operating Income
-$58.9m
CAGR 3-Years
N/A
CAGR 5-Years
-64%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Operating Income
-kr125.8m
CAGR 3-Years
-3%
CAGR 5-Years
-13%
CAGR 10-Years
-13%
B
Bergenbio ASA
OSE:BGBIO
Operating Income
-kr161.3m
CAGR 3-Years
20%
CAGR 5-Years
4%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Operating Income
-kr96.8m
CAGR 3-Years
-32%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Operating Income
-kr1.5m
CAGR 3-Years
N/A
CAGR 5-Years
31%
CAGR 10-Years
24%
T
Thor Medical ASA
OSE:TRMED
Operating Income
-kr20.3m
CAGR 3-Years
63%
CAGR 5-Years
44%
CAGR 10-Years
7%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Operating Income?
Operating Income
-58.9m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Operating Income amounts to -58.9m USD.

What is Nykode Therapeutics ASA's Operating Income growth rate?
Operating Income CAGR 5Y
-64%

Over the last year, the Operating Income growth was 3%.

Back to Top